Smith & Nephew plc vs Virgin Galactic Holdings, Inc. — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Virgin Galactic Holdings, Inc. trades at $2.97 (market cap $474.50M). The key difference: Smith & Nephew plc is far larger — about 24.5× Virgin Galactic Holdings, Inc.'s market cap, and Smith & Nephew plc pays a 2.85% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| SNN | SPCE | |
|---|---|---|
Market Cap | $11.63B | $474.50M |
Sector | Health | Industrials |
52-Week High | $38.53 | $7.52 |
52-Week Low | $27.80 | $2.17 |
Enterprise Value | $14.66B | $438.48M |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Virgin Galactic (SPCE) trades at $3.13, up 2.96% with a bullish technical outlook from moving averages. The company continues to report significant losses with negative profit margins and cash flow, though recent quarters have shown earnings beats. Management targets positive cash flow by 2027, but commercial spaceflight delays to February 2027 create execution risk. Analyst sentiment is divided with 29% buy, 41% hold, and 29% sell ratings.
SPCE represents a high-risk, speculative opportunity in the emerging space tourism sector. The path to profitability remains distant with substantial cash burn, though strong ticket demand provides potential upside if execution improves. Key risks include ongoing dilution, high short interest, and the capital-intensive nature of space operations. Investors should weigh the long-term potential against persistent financial challenges.
Trailing returns across standard periods
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →